113 related articles for article (PubMed ID: 1705633)
1. Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor.
Glassman HN; Kleinert HD; Boger RS; Moyse DM; Griffiths AN; Luther RR
J Cardiovasc Pharmacol; 1990; 16 Suppl 4():S76-81. PubMed ID: 1705633
[TBL] [Abstract][Full Text] [Related]
2. Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension.
Boger RS; Glassman HN; Cavanaugh JH; Schmitz PJ; Lamm J; Moyse D; Cohen A; Kleinert HD; Luther RR
Hypertension; 1990 Jun; 15(6 Pt 2):835-40. PubMed ID: 2190927
[TBL] [Abstract][Full Text] [Related]
3. Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat.
Neutel JM; Luther RR; Boger RS; Weber MA
Am Heart J; 1991 Oct; 122(4 Pt 1):1094-100. PubMed ID: 1656720
[TBL] [Abstract][Full Text] [Related]
4. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor.
Weber MA; Neutel JM; Essinger I; Glassman HN; Boger RS; Luther R
Circulation; 1990 Jun; 81(6):1768-74. PubMed ID: 2188754
[TBL] [Abstract][Full Text] [Related]
5. Renin inhibitors in hypertension.
Luther RR; Glassman HN; Boger RS
Clin Nephrol; 1991 Oct; 36(4):181-6. PubMed ID: 1959244
[TBL] [Abstract][Full Text] [Related]
6. Hemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans.
Delabays A; Nussberger J; Porchet M; Waeber B; Hoyos P; Boger R; Glassman H; Kleinert HD; Luther R; Brunner HR
Hypertension; 1989 Jun; 13(6 Pt 2):941-7. PubMed ID: 2661434
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor). I: Single dose study.
Gupta SK; Granneman GR; Boger RS; Hollenberg NK; Luther RR
Drug Metab Dispos; 1992; 20(6):821-5. PubMed ID: 1362933
[TBL] [Abstract][Full Text] [Related]
8. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure.
Neuberg GW; Kukin ML; Penn J; Medina N; Yushak M; Packer M
Am J Cardiol; 1991 Jan; 67(1):63-6. PubMed ID: 1986506
[TBL] [Abstract][Full Text] [Related]
9. Intrarenal angiotensin II formation in humans. Evidence from renin inhibition.
Fisher ND; Allan DR; Gaboury CL; Hollenberg NK
Hypertension; 1995 May; 25(5):935-9. PubMed ID: 7737730
[TBL] [Abstract][Full Text] [Related]
10. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
[TBL] [Abstract][Full Text] [Related]
11. Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans.
Fisher ND; Allan D; Kifor I; Gaboury CL; Williams GH; Moore TJ; Hollenberg NK
Hypertension; 1994 Jan; 23(1):44-51. PubMed ID: 8282330
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of three different potent renin inhibitors in primates.
Clozel JP; Fischli W
Hypertension; 1993 Jul; 22(1):9-17. PubMed ID: 8319997
[TBL] [Abstract][Full Text] [Related]
13. Disparity between blood pressure and PRA inhibition after administration of a renin inhibitor to anesthetized dogs: methodological considerations.
Palmer RK; Rapundalo ST; Batley BL; Barnes AE; Singh S; Ryan MJ; Taylor DG
Clin Exp Hypertens; 1993 Jul; 15(4):663-81. PubMed ID: 8374609
[TBL] [Abstract][Full Text] [Related]
14. Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans.
Cordero P; Fisher ND; Moore TJ; Gleason R; Williams GH; Hollenberg NK
Hypertension; 1991 Apr; 17(4):510-6. PubMed ID: 2013477
[TBL] [Abstract][Full Text] [Related]
15. Effects of renin inhibition in systemic hypertension.
Anderson PW; Do YS; Schambelan M; Horton R; Boger RS; Luther RR; Hsueh WA
Am J Cardiol; 1990 Dec; 66(19):1342-7. PubMed ID: 2244565
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure.
Gupta SK; Granneman GR; Packer M; Boger RS
J Cardiovasc Pharmacol; 1993 May; 21(5):834-40. PubMed ID: 7685457
[TBL] [Abstract][Full Text] [Related]
17. Effects of a novel renin inhibitor in patients with essential hypertension.
Bursztyn M; Gavras I; Tifft CP; Luther R; Boger R; Gavras H
J Cardiovasc Pharmacol; 1990 Mar; 15(3):493-500. PubMed ID: 1691375
[TBL] [Abstract][Full Text] [Related]
18. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide.
Villamil A; Chrysant SG; Calhoun D; Schober B; Hsu H; Matrisciano-Dimichino L; Zhang J
J Hypertens; 2007 Jan; 25(1):217-26. PubMed ID: 17143194
[TBL] [Abstract][Full Text] [Related]
19. Abnormal renin short feedback loop in essential hypertension is reversible with converting enzyme inhibition.
LeBoff Ms; Dluhy RG; Hollenberg NK; Moore TJ; Koletsky RJ; Williams GH
J Clin Invest; 1982 Aug; 70(2):335-41. PubMed ID: 6284799
[TBL] [Abstract][Full Text] [Related]
20. Intraocular pressure lowering effects of the renin inhibitor ABBOTT-64662 diacetate in animals.
Giardina WJ; Kleinert HD; Ebert DM; Wismer CT; Chekal MA; Stein HH
J Ocul Pharmacol; 1990; 6(2):75-83. PubMed ID: 2203852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
